SCHEMBL965629

SCHEMBL965629

COc1ccc(N2CCOCC2)cc1-c1nc(N(C)Cc2ccc(N3CCOCC3)cc2-c2nc(N(C)C)c3ccccc3n2)c2ccccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 11/20 0.50
CYP2D6 P10635 10/20 0.50
CYP3A4 P08684 9/20 0.50
TSHR P16473 8/20 0.50
ALDH1A1 P00352 6/20 0.50
USP2 O75604 5/20 0.50
ALOX15 P16050 4/20 0.50
LMNA P02545 3/20 0.50
HSD17B10 Q99714 3/20 0.50
TP53 P04637 1/20 0.50
CLK4 Q9HAZ1 7/20 0.49
MAPK1 P28482 6/20 0.49
CYP2C19 P33261 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
GBA1 P04062 1/20 0.43
MAPT P10636 7/20 0.42
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.40
HIF1A Q16665 2/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL940040 0.91 CYP1A2 (0.60) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL963568 0.82 CYP1A2 (0.60) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL965628 0.82 CYP1A2 (0.48) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL939175 0.78 CYP1A2 (0.47) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL939163 0.71 CYP2D6 (0.74) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL937503 0.70 MAPT (0.52) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL1084436 0.70 MAPT (0.48) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL1083943 0.70 CYP2D6 (0.72) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL1084145 0.70 CYP1A2 (0.81) CYP1A2CYP2D6CYP3A4TSHRALDH1A1
SCHEMBL938570 0.70 CYP2D6 (0.72) CYP1A2CYP2D6CYP3A4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-20110021495-A1 QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-27 US disclosed
US-20100160316-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-24 US disclosed
US-7713983-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-11 US disclosed
US-7678802-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-03-16 US disclosed
EP-1608632-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-12-30 EP disclosed
US-20060217377-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160316-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS KCNN3, KCNN2, CACNA1I CYP1A2 2515/4885CYP2D6 2468/4885CYP3A4 2226/4885
US-20110021495-A1 QUINAZOLES USEFUL AS MODULATORS OF ION CHANNELS KCNN3, CACNA1I, CACNA1B CYP1A2 1509/4885CYP2D6 1496/4885CYP3A4 1147/4885
US-20060217377-A1 Quinazolines useful as modulators of ion channels KCNN3, KCNN2, CACNA1I CYP1A2 2515/4885CYP2D6 2468/4885CYP3A4 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.